

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/070502 A1

(51) International Patent Classification⁷: **C07D 311/08**, 311/16, 311/20, 311/58, A61K 31/353, A61P 35/00, 35/02

(21) International Application Number: **PCT/AU02/00264**

(22) International Filing Date: 8 March 2002 (08.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 3633 8 March 2001 (08.03.2001) AU

(71) Applicant (for all designated States except US): **NOVO-GEN RESEARCH PTY LTD** [AU/AU]; 140 Wicks Road, North Ryde, New South Wales 2113 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEATON, Andrew** [AU/AU]; 2/46-48 Abbotsford Parade, Abbotsford, New South Wales 2046 (AU). **KELLY, Graham, Edmund** [AU/AU]; 47 Coolawin Street, Northbridge, New South Wales 2063 (AU). **KUMAR, Naresh** [AU/AU]; 33 White Avenue, Maroubra, New South Wales 2035 (AU).

(74) Agents: **HEISEY, Ross, Mitchell et al.**; **DAVIES COLLISON CAVE**, Level 10, 10 Barrack Street, Sydney, New South Wales 2000 (AU).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): **ARIPO patent** (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian patent** (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European patent** (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI patent** (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: **DIMERIC ISOFLAVONES**



WO 02/070502 A1



(I)



(II)

(57) Abstract: A compound of the general formula (I) or (II) wherein X is O, NR₄ or S and R₁-R₈ are as defined in the specification.

DIMERIC ISOFLAVONES

5 Field of the Invention

The present invention generally relates to novel dimeric molecules based on the 1,2-diphenylpropane (isoflavanoid) ring structure. The present invention further relates to the synthesis of the dimeric isoflavanoid molecules, compositions containing the same and their use as therapeutic agents.

10

Background of the Invention

Naturally-occurring plant isoflavones are known to possess a wide range of fundamental biological effects on human cells including anti-oxidation and the up-regulation and down-regulation of a wide variety of enzymes and signal transduction mechanisms. Mitotic arrest

15 and cytotoxicity of human cancer cells, increased capillary permeability, increased cellular adhesion, increased response of vascular smooth muscle cells to vaso-relaxants, and agonism of estrogen receptors, are just a few examples of the responses of animal cells to the biological effects of naturally-occurring isoflavonoids.

20 A range of therapeutic benefits as a result of these biological outcomes have been identified including the treatment and prevention of pre-menopausal symptoms such as pre-menstrual syndrome, endometriosis, uterine fibroids, hyperlipidaemia, cardiovascular disease, menopausal symptoms such as osteoporosis and senile dementia, alcoholism, benign prostatic hypertrophy, and cancers such as prostate, breast and large bowel. 25 carcinomas [see WO 93/23069; WO 96/10341; US 5424331; JP 62-106017; JP 62-106016; US 5516528; JP 62-106016A2; JP 62-106017A2; JP 61-246124; WO 98/50026; WO 99/43335; WO 00/49009; WO 00/644438; WO 99/48496].




30 While over 700 different naturally occurring isoflavones are described, only a few are confirmed as having potential therapeutic benefits in animals including humans. These include daidzein, genistein, formononetin, biochanin and glycinein. These and all naturally

- 2 -


occurring isoflavones are found in nature as the monomeric form either in a free state, or, more likely, bound to a carbohydrate moiety (glycoside). The isoflavone has to be separated from this moiety before it becomes biologically active.

5 A number of compounds with a structure related to naturally occurring plant isoflavones are also described as having biological properties with potential therapeutic benefit to animals including humans. These include compounds that are naturally occurring metabolites of plant isoflavones produced by bacterial fermentation by gut flora and embrace compounds such as equol and *o*-desmethylangolensin [WO 93/23069; WO
10 98/08503; WO 01/17986; WO 00/66576]. Also included in this group is the synthetic isoflavonoid ipriflavone, which is developed for the treatment of postmenopausal osteoporosis [WO 91/14429] and a wide range of synthetic isoflavonoid analogues [WO 98/08503].


15 Recently, some interest has been expressed in the biological properties of dimeric forms of isoflavonoids. Four forms of bis-isoflavones with the following structures are claimed to have 5-alpha-reductase inhibitory activity useful for the treatment of prostatomegaly [JP 9067362-A].



- 3 -



5 A C-C bridged bis-isoflavone dimer as shown below has also been described, but no biological activity or therapeutic benefit has been ascribed to it [Al-Maharik et al].





10 A requirement accordingly exists for new generation compounds that exhibit important pharmacological effects for use as prophylactics and in therapy.

Summary of the Invention

Surprisingly, the present inventors have discovered a new class of molecules based on 15 dimeric isoflavone compounds and derivatives. The dimeric molecules of the present invention generally show strong binding affinity for both estrogen receptors and hence exhibit remarkable physiological activity.

Thus according to a first aspect of the present invention there is provided a compound of 20 the general formulae (I) or (II):

- 4 -



5 wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H, OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,


R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

- 5 -

R₁₀ is independently hydrogen, alkyl or aryl,
 R₁₁ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and
 R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,
 X is O, NR₄ or S, and

5 the drawing "—" represents either a single bond or a double bond,
 which compounds include pharmaceutically acceptable salts thereof,
 with the proviso that in formula (I) at least one of R₅, R₆, R₇ and R₈ is hydrogen.

According to a second aspect of the present invention there is provided a process for the
 10 preparation of a compound of formulae (I) or (II) by reacting a compound of the formula
 (III)



15 wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H,
 OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl,
 thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,
 R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,
 20 R₁₀ is independently hydrogen, alkyl or aryl,
 R₁₁ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and
 R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,
 OR₁₃ is hydroxy, another leaving group or an electron withdrawing group,
 X is O, NR₄ or S, and

25 the drawing "—" represents either a single bond or a double bond,
 which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in the preparation of compounds of formula (I) at least one of R₅, R₆, R₇ and R₈ is hydrogen,
with a coupling agent.

- 5 It has surprisingly been found by the inventors that isoflavone dimers of the general formulae (I) and (II) have particular utility and effectiveness in the treatment, prophylaxis, amelioration defence against, and/or prevention of one or more of the following diseases and disorders (for convenience hereinafter referred to as the "therapeutic indications"):
 - (a) all forms of cancer (pre-malignant, benign and malignant) in all tissues of the body.
10 In this regard, the compounds may be used as the sole form of anti-cancer therapy or in combination with other forms of anti-cancer therapy including but not limited to radiotherapy and chemotherapy;
 - (b) diseases and disorders associated with inflammatory reactions of an abnormal or prolonged nature in any of the body's tissues including but not limited to rheumatoid arthritis, tendonitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease, sclerosing cholangitis;
15
 - (c) papulonodular skin lesions including but not limited to sarcoidosis, angiosarcoma, Kaposi's sarcome, Fabry's Disease
 - (d) papulosquamous skin lesions including but not limited to psoriasis, Bowen's Disease, and Reiter's Disease;
20
 - (e) actinic damage characterized by degenerative changes in the skin including but not limited to solar keratosis, photosensitivity diseases, and wrinkling;
 - (f) diseases and disorders associated with abnormal angiogenesis affecting any tissue within the body including but not limited to hemangiomas and telangiectasia;
 - (g) proliferative disorders of bone marrow including but not limited to megaloblastic disease, myelodysplastic syndromes, polycythemia vera, thrombocytosis and myelofibrosis;
25
 - (h) autoimmune disease characterized by abnormal immunological responses including but not limited to multiple sclerosis, Type 1 diabetes, systemic lupus erythematosus, and biliary cirrhosis;
30

- 7 -

- (i) neurodegenerative diseases and disorders characterized by degenerative changes in the structure of the neurological system including but not limited to Parkinson's Disease, Alzheimer's Disease, muscular dystrophy, Lou-Gehrig Disease, motoneurone disease;
- 5 (j) diseases and disorders associated with degenerative changes within the walls of blood vessels including but not limited to atherosclerosis, atheroma, coronary artery disease, stroke, myocardial infarction, hypertensive vascular disease, malignant hypertension, thromboangiitis obliterans, fibromuscular dysplasia;
- (k) diseases and disorders associated with abnormal immunological responses including
- 10 but limited to dermatomyositis and scleroderma;
- (l) diseases and disorders associated with degenerative changes within the eye including but not limited to cataracts, macular degeneration, retinal atrophy.

In particular the isoflavone dimers also surprisingly have been found to have a potent
15 effect on the production and function of reproductive hormones such as estrogens and androgens. As a result of this, these compounds may be used in the treatment and prevention of one or more of the following disorders and diseases:

- (a) conditions in women associated with abnormal estrogen/androgen balance including but not limited to cyclical mastalgia, acne, dysmenorrhoea, uterine
20 fibroids, endometriosis, ovarian cysts, premenstrual syndrome, acute menopause symptoms, osteoporosis, senile dementia, infertility; and
- (b) conditions in men associated with abnormal estrogen/androgen balance including but not limited to benign prostatic hypertrophy, infertility, gynecomastia, alopecia hereditaria and various other forms of baldness.

25 Thus, according to a third aspect of the present invention there is provided a method for the treatment, prophylaxis or amelioration of a disease or disorder which method includes the step of administering a therapeutically effective amount of one or more compounds of formulae (I) and (II) to a subject.

30 According to a fourth aspect of the present invention there is provided the use of one or

- 8 -

more compounds of formulae (I) and (II) in the manufacture of a medicament for the treatment of disease.

According to a fifth aspect of the present invention there is provided the use of one or more 5 compounds of formulae (I) and (II) as an anti-estrogen or selective estrogen receptor modulator (SERM).

According to a sixth aspect of the present invention there is provided an agent for the treatment, prophylaxis or amelioration of a disease which agent comprises one or more 10 compounds of formulae (I) or (II).

According to a seventh aspect of the present invention there is provided a pharmaceutical composition which comprises one or more compounds of formulae (I) and (II) in association with one or more pharmaceutical carriers and/or excipients.

15 According to a eighth aspect of the present invention there is provided a drink or food-stuff, which contains one or more compounds of formulae (I) and (II).

Throughout this specification and the claims which follow, unless the context requires 20 otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Detailed Description of the Invention

25 The dimeric molecules of the present invention are structurally related to monomeric isoflavone compounds and derivatives thereof. The term "isoflavone" as used herein is to be taken broadly to include ring-fused benzopyran molecules having a pendent phenyl group from the pyran ring based on a 1,2-diphenylpropane system. Thus, the classes of compounds generally referred to as isoflavones, isoflavenes, isoflavans, isoflavanones, 30 isoflavanols and the like are generically referred to herein as isoflavones, isoflavone derivatives or isoflavonoid molecules.

The term "alkyl" is taken to mean both straight chain and branched chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertiary butyl, and the like. The alkyl group has 1 to 10 carbon atoms, preferably from 1 to 6 carbon atoms, more

5 preferably methyl, ethyl propyl or isopropyl. The alkyl group may optionally be substituted by one or more of fluorine, chlorine, bromine, iodine, carboxyl, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylamino-carbonyl, di-(C₁-C₄-alkyl)-amino-carbonyl, hydroxyl, C₁-C₄-alkoxy, formyloxy, C₁-C₄-alkyl-carbonyloxy, C₁-C₄-alkylthio, C₃-C₆-cycloalkyl or phenyl.

10

The term "aryl" is taken to include phenyl and naphthyl and may be optionally substituted by one or more C₁-C₄-alkyl, hydroxy, C₁-C₄-alkoxy, carbonyl, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylcarbonyloxy or halo.

15 The term "halo" is taken to include fluoro, chloro, bromo and iodo, preferably fluoro and chloro, more preferably fluoro. Reference to for example "haloalkyl" includes monohalogenated, dihalogenated and up to perhalogenated alkyl groups. Preferred haloalkyl groups are trifluoromethyl and pentafluoroethyl.

20 The compounds of the invention include all salts, such as acid addition salts, anionic salts and zwitterionic salts, and in particular include pharmaceutically acceptable salts.

The term "pharmaceutically acceptable salt" refers to an organic or inorganic moiety that carries a charge and that can be administered in association with a pharmaceutical agent, 25 for example, as a counter-cation or counter-anion in a salt. Pharmaceutically acceptable cations are known to those of skilled in the art, and include but are not limited to sodium, potassium, calcium, zinc and quaternary amine. Pharmaceutically acceptable anions are known to those of skill in the art, and include but are not limited to chloride, acetate, citrate, bicarbonate and carbonate.

30

Dimeric isoflavone molecules and derivatives have only recently appeared in the literature.

- 10 -

Japanese patent application No. JP 9067362-A (Sankyo Co. Ltd.) describes bis-isoflavones joined either by the pendent phenyl groups or by one pendent phenyl group of one monomer to the aromatic benzopyran ring of the other isoflavone monomer. The bis-isoflavones are thought to be useful as 5-alpha reductase inhibitors.

5


The synthesis of C-C bridged bis-isoflavones has also been described by the nucleophilic substitution of 2-bromomethyl isoflavone derivatives (Al-Maharik *et al.*). The double alkylation reaction gives rise to bridged bis-isoflavones attached through the 2-methyl groups. No activity has been ascribed to these newly synthesised bis-isoflavones.

10

In contrast, the dimeric molecules of the present invention are linked through the 4-position of the isoflavone pyran ring to either of the two aromatic rings. That is, the 4-position of the pyran ring is linked to the aromatic benzopyran ring (formula I), or to the pendent phenyl group (formula II).


15

Preferred dimeric molecules of the present invention are depicted by the general formulae (Ia) and (IIa):



20

- 11 -



wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H,
 5 OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl,
 thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,

R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

R₁₀ is independently hydrogen, alkyl or aryl,

R₁₁ is hydrogen alkyl, aryl, arylalkyl or an amino acid, and

10 R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

X is O, NR₄ or S, and

the drawing "—" represents either a single bond or a double bond,

which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in Formula (Ia) at least one of R₅, R₆, R₇ and R₈ is hydrogen;

15

more preferably they have the following substituents wherein

R₁, R₂, R₃, R₄, R₅, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉,
 OS(O)R₉, alkyl, aryl, arylalkyl, thio, alkylthio, bromo, chloro or fluoro,

R₆ is hydrogen,

20 R₉ is alkyl, fluoroalkyl or arylalkyl, and

X is O;

- 12 -

more preferably they have the following substituents wherein

R₁ and R₆ are hydrogen,

R₂, R₃, R₅ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉, alkyl, aryl or

5 arylalkyl,

R₄ and R₇ are independently hydroxy, OR₉ or OC(O)R₉,

R₉ is methyl, ethyl, propyl, isopropyl or trifluoromethyl, and

X is O; and

10 most preferably they have the following substituents wherein

R₁ and R₆ are hydrogen,

R₂, R₃, R₅ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉ or methyl,

R₄ and R₇ are independently hydroxy, OR₉ or OC(O)R₉,

R₉ is methyl, and

15 X is O.

Most preferably the novel dimeric compounds of formulae (I) and (II) are:

Tetraacetoxy 6-(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (2)

6-(4-(Isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (3)

20 Tetraacetoxy 6-(4-(isoflavan-4',7-diol))-isoflavan-4',7-diol (4)

6-(4-(Isoflavan-4',7-diol))-isoflavan-4',7-diol (5)

6-(4-(4',7-Dimethoxyisoflavan))-4',7-dimethoxyisoflav-3-ene (6)

6-(4-(4',7-Dimethoxyisoflavan))-4',7-dimethoxyisoflavan (7)

25 Tetraacetoxy 3'-(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (8)



3'-(4-(Isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (9)

Tetraacetoxy 3'-(4-(isoflavan-4',7-diol))-isoflavan-4',7-diol (10)


3'-(4-(Isoflavan-4',7-diol))-isoflavan-4',7-diol (11)

30 Compounds 2-11 are depicted by the following structural formulae:



- 13 -



5



- 14 -




5

Without wishing to be limited to theory, it is believed that the dimeric molecules of the present invention are formed as a result of an electrophilic aromatic substitution of one of the aromatic rings. Generally, plant-based isoflavone compounds have hydroxy groups in the 4'- and 7-positions, at least, on the isoflavone skeleton. These electron donating groups are thought to assist the electrophilic aromatic substitution and to direct substitution *ortho* or *para* to the electron donating substituent.

In a particularly preferred embodiment of the invention, the isoflavone diacetoxy tetrahydrodiadzein (1), R=Ac, is coupled to form a dimeric molecule upon dehydration of the monomer with phosphorus pentoxide.

- 15 -



(1)

Electrophilic substitution of the ring-fused benzene ring of (1) occurs preferentially alpha to the 7-oxy substituent and beta to the ring junction. The beta position is thought to be 5 more available due to smaller steric constraints than that of the position alpha to the ring junction. The pyran oxygen is thought to assist in the selectivity of substitution by activation of the ring fused benzene to electrophilic aromatic substitution, in preference to substitution of the pendent phenyl group.

10 Other synthetic methods well known to those skilled in the art may also be employed in the synthesis of the dimeric molecules of the present invention. Such other suitable synthetic methods include Friedel-Crafts alkylation coupling of two isoflavones or derivatives thereof. Typical Friedel-Crafts reaction conditions are used with reagents such as aluminium chloride, boron trifluoride or similar Lewis acid catalysts. The coupling 15 reaction is not limited to Friedel-Crafts type conditions, but may include other reaction conditions that can generate a "carbocation" species such as the conversion of a secondary alcohol to a phosphinic ester or similar facile leaving group. Oxidative coupling reaction conditions such as hydrogen peroxide, dilute permanganate, phosphorous pentoxide or other oxidative compounds may also be employed in the synthesis of the dimeric 20 molecules of the invention.

Linking two monomeric isoflavone compounds or derivatives with a bridging group may also lead to dimeric isoflavone molecules of the present invention. Suitable divalent bridging groups include, for example, -O-, -S-, -CH₂-, -(C(R)H)_n-, -NR-, or -C=O.

25

Chemical functional group protection, deprotection, synthons and other techniques known to those skilled in the art may be used where appropriate to aid in the synthesis of the

compounds of the present invention, and their starting materials.

The preferred starting isoflavone monomer, diacetoxy tetrahydrodaidzein (1) R=Ac, may be obtained by standard procedures known in the art. Particular reference is made to 5 published International patent applications WO 98/08503 and WO 00/49009, and references cited therein, (Novogen Research Pty Ltd) for useful synthetic methods for the production of (1) and related isoflavones.

However, the isoflavone monomers for use in the present invention may be derived from 10 any number of sources readily identifiable to a person skilled in the art. By way of example, the isoflavones may be purchased commercially or extracted from plant sources. Those skilled in the art will readily be able to identify suitable plant species which may be used to derive suitable isoflavone extracts for use in the present invention, however, plants of particular use in the invention include chickpea, soy and clover species, for example. 15 More preferably, an isoflavone extract is obtained from red clover or subterranean clover species.

An isoflavone extract may be prepared by any number of techniques known in the art. For example, suitable isoflavone extracts may be prepared by water/organic solvent extraction 20 from the native plant source. It will be appreciated that an isoflavone extract may be prepared from any single tissue of a single species of plant or a combination of two or more different tissues thereof. Similarly, an extract may be prepared from a starting material which contains a heterogeneous mixture of tissues from two or more different species of plant.

25

Generally, where an isoflavone extract is prepared from plant material, the material may be comminuted or chopped into smaller pieces, partially comminuted or chopped into smaller pieces and contacted with water and an organic solvent, such as a water miscible organic solvent. Alternatively, the plant material is contacted with water and an organic solvent 30 without any pre-treatment. The ratio of water to organic solvent may be generally in the range of 1:10 to 10:1 and may, for example, comprise equal proportions of water and

solvent, or from 1% to 30% (v/v) organic solvent. Any organic solvent or a mixture of such solvents may be used. The organic solvent may preferably be a C2-10, more preferably a C1-4 organic solvent (such as methanol, chloroform, ethanol, propanol, propylene glycol, erythrite, butanol, butanediol, acetonitrile, ethylene glycol, ethyl acetate, 5 glycidol, glycerol dihydroxyacetone or acetone). Optionally the water/organic solvent mixture may include an enzyme which cleaves isoflavone glycosides to the aglycone form. The mixture may be vigorously agitated so as to form an emulsion. The temperature of the mix may range, for example, from an ambient temperature to boiling temperature. Exposure time may be between one hour to several weeks. One convenient extraction 10 period is twenty-four hours at 90°C. The extract may be separated from undissolved plant material and the organic solvent removed, such as by distillation, rotary evaporation, or other standard procedures for solvent removal. The resultant extract containing water soluble and non-water soluble components may be dried to give an isoflavone-containing extract, which may be formulated with one or more pharmaceutically acceptable carriers, 15 excipients and/or auxiliaries according to the invention.

An extract made according to the description provided in the previous paragraphs may contain small amounts of oil which include isoflavones in their aglycone form (referred to herein as isoflavones). This isoflavone enriched oil, may be subject to HPLC to adjust the 20 isoflavone ratios, or, if it is at the desired isoflavone ratio, may be dried, for example in the presence of silica, and be formulated with one or more carriers, excipients and/or auxiliaries to give an isoflavone containing extract. Alternatively, the isoflavones contained in said small amounts of oil may be further concentrated by addition to the oil of a non-water soluble organic solvent such as hexane, heptane, octane acetone or a mixture 25 of one or more of such solvents. One example is 80% hexane, 20% acetone w/w having high solubility for oils but low solubility for isoflavones. The oil readily partitions into the organic solvent, and an enriched isoflavone containing extract falls out of solution. The recovered extract may be dried, for example in an oven at 50°C to about 120°C, and formulated with one or more pharmaceutically acceptable carriers, excipients and/or 30 auxiliaries.

- 18 -

Other suitable methods may be found in, for example, Chang *et al* which discloses methods appropriate for the synthesis of various isoflavones and derivatives thereof.

The dimeric isoflavone structures depicted in formulae (Ia) and (IIa) possess an inherent ability to restrict the conformation between the two monomeric structures to an orthogonal relationship. It is hypothesised that the apparent greater conformational rigidity of the orthogonal relationship and the inherent ability to define a displacement of H bond donors in the ligand binding domain monomeric section of the dimer leads to moderation of the normal agonistic actions of the monomer for cellular receptors. In most cases that moderation results in up-regulation of the biological activity, while in some cases it results in down-regulation of that activity. That is, the biological profile of the monomer which to a large extent is predictable based on the known structure-function relationship established from the experience with screening large libraries of such compounds, is unpredictable with the dimeric forms. Functions which are moderated with the conversion from the monomeric to the dimeric forms are as follows: absolute levels of agonism and antagonism of hER- α and hER- β as well as the relative levels of agonism/antagonism of both receptor types; inhibition of 5- α - reductase and 17 β -steroidalaldehydehydrogenase; anti-oxidation; mitotic arrest and induction of apoptosis of cancer cells; prostaglandin and inflammatory cytokine release; vasoactivity; high density lipoprotein and low density lipoprotein levels.

20

Thus the present inventors have surprisingly found that the dimeric molecules of the present invention present a family of new compounds that are indicated for the treatment and prevention of a range of important human diseases and disorders set out above. These diseases and disorders include cancers, inflammatory disorders, autoimmune disorders, 25 cardiovascular disorders, and disorders associated with estrogen receptor activation.

In particular, the dimeric compounds of the present invention through their potent ability to inhibit proliferation of cancer cells and to induce apoptosis show use in the prevention and treatment of cancers, a term which any person skilled in the art would understand embraces 30 aberrant growth of both a benign and malignant nature of any or all tissues in the body across epithelial, mesenchymal and neural types. This includes, but is not restricted to,

carcinomas, adenocarcinomas, sarcomas, blastomas, adenomas, lymphomas, leukaemias, gliomas and melanoma.

In particular, the dimeric compounds of the present invention through their potent ability to

5 act as h-ER β agonists are able to provide oestrogenic support in particular to women of peri-menopausal and menopausal age and to prevent and to treat problems generally recognised as representing acute withdrawal of steroidal estrogen such as vasomotor symptoms (hot flushes and night sweats) and emotional symptoms (anxiety, depression, mood swings), problems generally recognised as representing sub-acute withdrawal of

10 10 steroidal estrogen such as urinary incontinence and bladder prolapse, and problems generally recognised as representing chronic withdrawal of steroidal estrogen such as osteopaenia and osteoporosis, and senile dementia.

In particular, the dimeric compounds of the present invention through their potent ability to

15 act as h-ER α antagonists are able to prevent or to treat conditions in pre-menopausal women generally regarded as being associated with excessive stimulation of h-ER α receptors and leading to such conditions as cyclic mastalgia, endometriosis, endometrial hyperplasia, uterine fibroids, polycystic ovarian disease, and pre-menstrual syndrome.

20 In particular, the dimeric compounds of the present invention through their potent ability to induce vasodilation and to reduce vasospasm show use in the treatment and prevention of disorders generally recognised as being associated with vasopression either causally or indirectly and embracing but not limited to hypertension and migraine headache.

25 In particular, the dimeric compounds of the present invention through their potent ability to antagonise inflammatory processes and to moderate immunological processes show use in the prevention and treatment of disorders generally recognised as being associated with excessive inflammation or dysfunctional immune function and embracing but not limited

30 30 to inflammatory conditions of the gastrointestinal tract including inflammatory bowel

disease, ulcerative colitis, Crohn's disease, and sclerosing cholangitis, and inflammatory disorders of synovial membranes including rheumatoid arthritis.

In particular, the dimeric compounds of the present invention through their potent ability to

5 act as anti-oxidants show use in the prevention and treatment of conditions generally recognised as being associated with oxidation leading to degenerative changes and including but not limited to conditions such as cataracts, actinic damage, and atherosclerosis.

10 In particular, the dimeric compounds of the present invention through their potent ability to inhibit androgenesis show use in the prevention and treatment of conditions generally recognised as being associated (either causally or indirectly) with aberrant function of androgens and including but not limited to male pattern baldness (alopecia hereditaria) and prostatic adenoma.

15 The amount of one or more compounds of formulae I and II which is required in a therapeutic treatment according to the invention will depend upon a number of factors, which include the specific application, the nature of the particular compound used, the condition being treated, the mode of administration and the condition of the patient.

20 Compounds of formulae I or II may be administered in a manner and amount as is conventionally practised. See, for example, Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, 1299 (7th Edition, 1985). The specific dosage utilised will depend upon the condition being treated, the state of the subject, the route of administration and other well known factors as indicated above. In general, a daily dose per patient may be in

25 the range of 0.1 mg to 2 g; typically from 0.5 mg to 1 g; preferably from 20 mg to 200 mg.

30 The production of pharmaceutical compositions for the treatment of the therapeutic indications herein described are typically prepared by admixture of the compounds of the invention (for convenience hereafter referred to as the "active compounds") with one or more pharmaceutically or veterinarily acceptable carriers and/or excipients as are well known in the art.

The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the subject. The carrier or excipient may be a solid or a liquid, or both, and is preferably formulated with the

5 compound as a unit-dose, for example, a tablet, which may contain from 0.5% to 59% by weight of the active compound, or up to 100% by weight of the active compound. One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.

10

The formulations of the invention include those suitable for oral, rectal, optical, buccal (for example, sublingual), parenteral (for example, subcutaneous, intramuscular, intradermal, or intravenous) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the

15 nature of the particular active compound which is being used.

Formulation suitable for oral administration may be presented in discrete units, such as capsules, sachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or

20 non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely

25 divided solid carrier, or both, and then, if necessary, shaping the resulting mixture such as to form a unit dosage. For example, a tablet may be prepared by compressing or moulding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound of the free-flowing, such as a powder or granules optionally mixed

30 with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Moulded

- 22 -

tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sublingual) administration include lozenges comprising
5 the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Compositions of the present invention suitable for parenteral administration conveniently
10 comprise sterile aqueous preparations of the active compounds, which preparations are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and
15 rendering the resulting solution sterile and isotonic with the blood. Injectable formulations according to the invention generally contain from 0.1% to 60% w/v of active compound and are administered at a rate of 0.1 ml/minute/kg.

Formulations suitable for rectal administration are preferably presented as unit dose
20 suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations or compositions suitable for topical administration to the skin preferably take
25 the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers that may be used include Vaseline, lanoline, polyethylene glycols, alcohols, and combination of two or more thereof. The active compound is generally present at a concentration of from 0.1% to 0.5% w/w, for example, from 0.5% to 2% w/w. Examples of such compositions include cosmetic skin creams.

- 23 -

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound as an optionally buffered aqueous solution of, for example, 0.1 M to 0.2 M concentration with respect to
5 the said active compound.

Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, *Panchagnula et al*) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations
10 comprise citrate or Bis/Tris buffer (pH 6) or ethanol/water and contain from 0.1 M to 0.2 M active ingredient.

The active compounds may be provided in the form of food stuffs, such as being added to, admixed into, coated, combined or otherwise added to a food stuff. The term food stuff is
15 used in its widest possible sense and includes liquid formulations such as drinks including dairy products and other foods, such as health bars, desserts, etc. Food formulations containing compounds of the invention can be readily prepared according to standard practices.

20 Formulations suitable for inhalation may be delivered as a spray composition in the form of a solution, suspension or emulsion. The inhalation spray composition may further comprise a pharmaceutically acceptable propellant such as carbon dioxide or nitrous oxide.

The compositions of the invention may also be administered to a human in a dietary
25 supplement form. Dietary supplements incorporating the actives can be prepared by adding the composition to a food in the process of preparing the food. Any food may be used including, but not limited thereto, meats such as ground meats, emulsified meats and marinated meats; beverages such as nutritional beverages, sports beverages, protein fortified beverages, juices, milk, milk alternatives, and weight loss beverages; cheeses such
30 as hard and soft cheeses, cream cheese, and cottage cheese; frozen desserts such as ice cream, ice milk, low fat frozen desserts, and non-dairy frozen desserts; yogurts; soups;

puddings; bakery products; salad dressings; and dips and spreads such as mayonnaise, margarine, butter, butter substitute, and other fat containing spreads. The composition is added to the food in an amount selected to deliver a desired dose of the composition to the consumer of the food.

5

Compounds of the present invention have potent antioxidant activity and thus find wide application in pharmaceutical and veterinary uses, in cosmetics such as skin creams to prevent skin ageing, in sun screens, in foods, health drinks, shampoos, and the like.

10 It has surprisingly been found that compounds of the formulae I or II interact synergistically with vitamin E to protect lipids, proteins and other biological molecules from oxidation.

15 Accordingly a further aspect of this invention provides a composition comprising one or more compounds of formulae I and II, vitamin E, and optionally a pharmaceutically, 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

undesirable. The term also includes carriers, excipients, auxiliaries or diluents that are acceptable for veterinary use as well as human pharmaceutical use. As used herein the term "pharmaceutically acceptable carriers, excipients, auxiliaries and/or diluents" includes one of, or more than one of, such substances.

5

The invention is further described with reference to the following non-limiting examples.

Examples

Example 1: Synthesis of tetra-acetoxy 6(3-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol

10 (2)

A mixture of approximately 1:1 *cis*-and *trans*-diacetoxytetrahydrodaidzein (1) (300g) is dissolved in dry dichloromethane and stirred under a bed of nitrogen at 15°C until all material has dissolved. Phosphorous pentoxide (500g) is added quickly with vigorous stirring and the reaction is continued for 4-6 hours. The reaction mixture is then filtered through a bed of silica gel with the dimeric structure having a lower R_f than the monomeric side product. The dimeric compound is further purified by selective recrystallisation from ethyl acetate.

^1H NMR (CDCl₃, 400MHz): 7.40 (2H, d, J=8Hz), 7.15 (2H, d, J=8Hz), 7.13 (2H, d, J=8Hz), 7.05 (2H, d, J=8Hz), 6.90 (1H, d J=7.6Hz), 6.75 (1H, d, J=1.5Hz), 6.65 (1H, bs s), 6.63 (1H, br s), 6.60 (1H, dd, J=7.6, 1.5Hz), 6.58 (1H, br s), 5.05 (2H, brs), 4.38 (1H, dd, J=9,3Hz), 4.30 (1H br d, J=7Hz), 4.25 (1H, dd, J=9,6Hz), 3.38 (1H, m), 2.32 (3H, s), 2.30 (3H, s) 2.28 (3H, s), 2.08 (3H, br s)

25

Example 2: Synthesis of 6(3-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (3)

Imidazole (0.166g) was added to a suspension of tetra-acetoxy 6(3-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (0.2g) in absolute ethanol (2.0ml). The mixture was refluxed under nitrogen for 12 hours. The solution was concentrated under vacuum and the product was precipitated by addition of deionised water (10ml). The mixture was left in the fridge

overnight. The off-white solid was filtered and freeze-dried to afford (0.1g, 67%) of the free phenolic dimeric compound.

¹H NMR (D6-DMSO, 400MHz): 9.1 (4H, br, OH), 7.26 (2H, d, J=7.6Hz), 7.04 (2H, d, J=7.6Hz), 6.72 (2H, d, J=7.6Hz), 6.61 (1H, s), 6.60 (2H, d, J=7.6Hz), 6.56 (1H, s), 6.46 (1H, d, J=8Hz), 6.25 (1H, s), 6.22 (1H, brd, J=8Hz), 6.20 (1H, brs), 4.95 (2H, s), 4.44 (1H, d, J=8.4Hz), 4.13 (1H, dd, J=11, 3.3Hz), 4.06 (1H, dd, J=11, 7.7Hz), 3.28 (1H, ddd, J=8.4, 7.7, 3.3Hz).

10 **Example 3: Estrogen Receptor Binding Assay**

The ability of the tetraphenolic dimer (Structure 3) and tetraacetoxy dimer (Structure 2) to interact with estrogen receptor alpha and beta was determined using a commercially available estrogen receptor binding kit. This kit employs a competitive binding assay to determine the relative binding affinity of test compounds for recombinant human estrogen receptors-alpha (ER- α) and beta (ER- β). Briefly, recombinant human estrogen receptor alpha or beta is added to fluorescently labelled estrogen ligand to form an estrogen ligand/receptor complex which exhibits high fluorescence polarization. The complex is then added to decreasing concentrations of competitor test compounds. The shift in polarization in the presence of test compound is used to determine the relative affinity of test compounds for the estrogen receptor. When assayed using the manufacturer's specifications, we determined the concentration of estradiol required to displace 50% of bound fluorescent estrogen ligand (EC₅₀) at 0.011 μ M for ER-alpha and 0.006 μ M for ER-beta which is in agreement with published values (Bolger *et al.*, 1998). The tetraphenolic dimer (Structure 3) demonstrated equal binding affinity for estrogen receptor alpha and beta (ER- α 0.35 \pm 0.05 μ M; ER- β 0.37 \pm 0.05 μ M.), however the tetraacetoxy dimer (Structure 2) did not bind either receptor.

Example 4: Anticancer Activity

The anticancer potential of the tetraphenolic dimer (Structure 3) and the tetraacetoxy dimer (Structure 2) was assessed using a panel of human tumour cell lines, including glioma (C6), prostate (PC3), breast (MCF-7), soft tissue (Kym-1) and lung (NCI-H23 and NCI-

H460). The cell cytotoxicity assay was conducted as per the method of Alley *et al.*, 1988. Cell lines are exposed to varying concentrations of test compound for a fixed time. At the conclusion of the assay, the viability of the cell population is determined using the hydrogen acceptor reagent 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT). The concentration of compound required to inhibit 50% of cell growth in comparison to a control (IC₅₀) is an indicator of effectiveness of the compound. (i.e. the lower the concentration of compound required to inhibit 50% of normal cell proliferation, the more efficacious). Both dimers exhibited potent anticancer activity against the cancer types tested (Table 1).

10

Table 1. IC50 determinations for both dimeric isoflavones against tumour cell lines.

Dimer	Cell Line IC50 (μM)					
	MCF-7	PC3	C6 Glioma	Kym-1	NCI- H460	NCI-H23
Structure 3	18 ± 2	13.5	17.5	3.2	14.4	13.5
Structure 2	10 ± 5	6	NT	NT	NT	7.3

NT = not tested

15

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in the field of endeavour.

20

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification individually or collectively, and any and all combinations of any two or more of said steps or features.

25

References**Patents:**

JP 9067362-A A; Patent Assignee Sankyo Co Ltd; "New bis-iso-flavone(s) as 5-alpha-reductase inhibitors - prepared from Microbiospora, used for treatment of 5 prostatomegally."

WO 00/49009; Patent assignee Novogen Research Pty Ltd; "Production of Isoflavone derivatives"

10 WO 91/14429; Chiesi P and Pavesi L Patent; Assignee: Chiesi; "Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use."

WO 93/23069; Kelly "GE Health Supplements".

15 WO 96/10341; Schouten Food and Health Products

US 5424331; Shlyankevich; "Pharmaceutical Compositions and Dietary Soybean Food Products for the Prevention of Osteoporosis".

20 JP 62-106017; Yamamoto Pharmaceuticals Co Ltd; "Anticancer agent for all isoflavonoid agents".

JP 62-106016; Yamanouchi Pharmaceuticals Co Ltd; "Therapeutic claims over 25 isoflavonoids as immuno-suppressive".

US 5516528; Hughes et al; "Dietary phytoestrogen in estrogen replacement therapy". (Assignees: Wake Forest Uni and PTI)

- 29 -

JP 62-106016A2; Immunosuppressor; Yamanouchi Pharmaceutical Co Ltd; "Isoflavones for remedy and the prevention of relapse of autoimmune diseases such as rheumatoid arthritis, SLE etc".

5 WO 01/17986; Novogen Research; Compositions and therapeutic methods involving isoflavones."

JP 62-106017A2; Anti-tumor agent; Yamanouchi Pharmaceut. Co Ltd; "oncogene originated tyrosine-specific phosphorylase-inhibiting activity".

10

JP 61-246124; A Carcinostatic Agent; Yamanouchi Pharmaceut. Co Ltd; "carcinostatic agent containing genistein".

15 WO 98/50026; Kelly GE; "Treatment or prevention of menopausal symptoms or osteoporosis – comprises administering the iso-flavone(s) formononetin or daidzein".

WO 99/43335; Huang LJ and Thurn MJ; "Plant extracts from clover"

WO 00/49009; Heaton A and Kumar N; "Production of isoflavone derivatives".

20

WO 00/644438; Husband AJ and Kelly GE; "Composition for treatment of cardiovascular diseases and osteoporosis comprises high proportion of formononetin with biochanin, genistein and/or genistein".

25 WO 99/48496; Husband AJ and Kelly GE; "Treating disorders associated with high steroidal estrogen activity e.g. uterine fibroids".

30

- 30 -

Articles:

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res.* 48, 589-5 601.

Al-Maharik NI, Kaltia SAA, Mutikainen I, Wahala K. Synthesis of C-C-Bridged Bis-Isoflavones. *Journal of Organic Chemistry* 65, 2305-2308, 2000

10 Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phyto-oestrogens: where are we now? *British Journal Of Nutrition* 79(5): 393-406 1998

Bolger R, Wiese TE, Ervin K, Nestich S, Checovich W (1998) Rapid screening of environmental chemicals for estrogen receptor binding capacity. *Environ Health Perspect*; 15 106, 551-7.

Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, 1299 7th Edition, 1985

20 Moss RW, Cancer Therapy: the Independent Consumer's Guide to Non-Toxic Treatment and Prevention (New York: Equinox Press, 1992)

Panchagnula *et al.* (2000) Transdermal iontophoresis revisited. *Current Opinion in Chemical Biology* 4: 468-473



25 Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other

Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells *Anticancer Research* 16:1657-1662 1999

- 32 -

CLAIMS:

1. A compound of the general formulae (I) or (II):




- 33 -


wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H, OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,
 R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,
 R₁₀ is independently hydrogen, alkyl or aryl,
 R₁₁ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and
 R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,
 X is O, NR₄ or S, and
 the drawing "—" represents either a single bond or a double bond,
 which compounds include pharmaceutically acceptable salts thereof,
 with the proviso that in formula (I) at least one of R₅, R₆, R₇ and R₈ is hydrogen.

2. A compound of claim 1 selected from the compounds of general formulae (Ia) and (IIa):



- 34 -



wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H, OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,

R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

R₁₀ is independently hydrogen, alkyl or aryl,

R₁₁ is hydrogen alkyl, aryl, arylalkyl or an amino acid, and

R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

X is O, NR₄ or S, and

the drawing "—" represents either a single bond or a double bond,

which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in Formula (Ia) at least one of R₅, R₆, R₇ and R₈ is hydrogen.

3. A compound of claim 2, wherein

R₁, R₂, R₃, R₄, R₅, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉, OS(O)R₉, alkyl, aryl, arylalkyl, thio, alkylthio, bromo, chloro or fluoro,

R₆ is hydrogen,

R₉ is alkyl, fluoroalkyl or arylalkyl, and

X is O.

4. A compound of claim 3, wherein

R₁ and R₆ are hydrogen,

R₂, R₃, R₅ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉, alkyl, aryl or arylalkyl,

R₄ and R₇ are independently hydroxy, OR₉ or OC(O)R₉,

R₉ is methyl, ethyl, propyl, isopropyl or trifluoromethyl, and

X is O.

5. A compound of claim 4, wherein

R₁ and R₆ are hydrogen,

R₂, R₃, R₅ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)R₉ or methyl,

R₄ and R₇ are independently hydroxy, OR₉ or OC(O)R₉,

R₉ is methyl, and

X is O.

6. A compound of claim 5 selected from:

Tetraacetoxy 6-(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (2)

6-(4-(Isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (3)

Tetraacetoxy 6-(4-(isoflavan-4',7-diol))-isoflavan-4',7-diol (4)

6-(4-(Isoflavan-4',7-diol))-isoflavan-4',7-diol (5)

6-(4-(4',7-Dimethoxyisoflavan))-4',7-dimethoxyisoflav-3-ene (6)

6-(4-(4',7-Dimethoxyisoflavan))-4',7-dimethoxyisoflavan (7)

Tetraacetoxy 3'-(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (8)


3'-(4-(Isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (9)

Tetraacetoxy 3'-(4-(isoflavan-4',7-diol))-isoflavan-4',7-diol (10)

3'-(4-(Isoflavan-4',7-diol))-isoflavan-4',7-diol (11).

7. A process for the preparation of a compound of formulae (I) or (II) which process comprises reacting a compound of the formula (III)

- 36 -



wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H, OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,

R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

R₁₀ is independently hydrogen, alkyl or aryl,

R₁₁ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and

R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

OR₁₃ is hydroxy, another leaving group or an electron withdrawing group,

X is O, NR₄ or S, and

the drawing "—" represents either a single bond or a double bond,

which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in the preparation of compounds of formula (I) at least one of R₅, R₆,

R₇ and R₈ is hydrogen,

with a coupling agent.

8. A process of claim 7, wherein the compound of formulae (I) or (II) is as defined in any one of claims 2 to 6.

9. A process of claim 7 or 8, wherein the coupling agent is phosphorus pentoxide, hydrogen peroxide, permanganate or a Lewis acid.

10. A method for the treatment, prophylaxis or amelioration of a disease or disorder which method includes the step of administering a therapeutically effective amount of one

or more compounds of formulae (I) and (II) to a subject, wherein the disease or disorder is selected from the group selected from

- a) all forms of cancer (pre-malignant, benign and malignant) in all tissues of the body. In this regard, the compounds may be used as the sole form of anti-cancer therapy or in combination with other forms of anti-cancer therapy including but not limited to radiotherapy and chemotherapy;
- b) diseases and disorders associated with inflammatory reactions of an abnormal or prolonged nature in any of the body's tissues including but not limited to rheumatoid arthritis, tendonitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease, sclerosing cholangitis;
- c) papulonodular skin lesions including but not limited to sarcoidosis, angiosarcoma, Kaposi's sarcoma, Fabry's Disease
- d) papulosquamous skin lesions including but not limited to psoriasis, Bowen's Disease, and Reiter's Disease;
- e) actinic damage characterized by degenerative changes in the skin including but not limited to solar keratosis, photosensitivity diseases, and wrinkling;
- f) diseases and disorders associated with abnormal angiogenesis affecting any tissue within the body including but not limited to hemangiomas and telangiectasia;
- g) proliferative disorders of bone marrow including but not limited to megaloblastic disease, myelodysplastic syndromes, polycythemia vera, thrombocytosis and myelofibrosis;
- h) autoimmune disease characterized by abnormal immunological responses including but not limited to multiple sclerosis, Type 1 diabetes, systemic lupus erythematosus, and biliary cirrhosis;
- i) neurodegenerative diseases and disorders characterized by degenerative changes in the structure of the neurological system including but not limited to Parkinson's Disease, Alzheimer's Disease, muscular dystrophy, Lou-Gehrig Disease, motoneurone disease;
- j) diseases and disorders associated with degenerative changes within the walls of blood vessels including but not limited to atherosclerosis, atheroma, coronary

artery disease, stroke, myocardial infarction, hypertensive vascular disease, malignant hypertension, thromboangiitis obliterans, fibromuscular dysplasia;

- k) diseases and disorders associated with abnormal immunological responses including but limited to dermatomyositis and scleroderma;
- l) diseases and disorders associated with degenerative changes within the eye including but not limited to cataracts, macular degeneration, retinal atrophy.

11. A method of claim 10, wherein the disorder or disease is selected from:

- (i) conditions in women associated with abnormal estrogen/androgen balance including but not limited to cyclical mastalgia, acne, dysmenorrhoea, uterine fibroids, endometriosis, ovarian cysts, premenstrual syndrome, acute menopause symptoms, osteoporosis, senile dementia, infertility; and
- (ii) conditions in men associated with abnormal estrogen/androgen balance including but not limited to benign prostatic hypertrophy, infertility, gynecomastia, alopecia hereditaria and various other forms of baldness.

12. Use of one or more compounds of formulae (I) and (II) in the manufacture of a medicament for the treatment of a disorder or disease.

13. Use of one or more compounds of formulae (I) and (II) as an anti-estrogen or selective estrogen receptor modulator (SERM).

14. An agent for the treatment, prophylaxis or amelioration of a disease or disorder which agent comprises one or more compounds of formulae (I) or (II).

15. A pharmaceutical composition which comprises one or more compounds of formulae (I) and (II) in association with one or more pharmaceutical carriers and/or excipients.

16. A drink or food-stuff, which contains one or more compounds of formulae (I) and (II).

17. A composition comprising one or more compounds of formulae (I) and (II), vitamin E, and optionally a pharmaceutically, veterinarily or cosmetically acceptable carriers and/or excipients.

undesirable. The term also includes carriers, excipients, auxiliaries or diluents that are acceptable for veterinary use as well as human pharmaceutical use. As used herein the term "pharmaceutically acceptable carriers, excipients, auxiliaries and/or diluents" includes one of, or more than one of, such substances.

5

The invention is further described with reference to the following non-limiting examples.

Examples

Example 1: Synthesis of tetra-acetoxy 6(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol

10 (2)

A mixture of approximately 1:1 *cis*-and *trans*-diacetoxytetrahydrodaidzein (1) (300g) is dissolved in dry dichloromethane and stirred under a bed of nitrogen at 15°C until all material has dissolved. Phosphorous pentoxide (500g) is added quickly with vigorous stirring and the reaction is continued for 4-6 hours. The reaction mixture is then filtered through a bed of silica gel with the dimeric structure having a lower R_f than the monomeric side product. The dimeric compound is further purified by selective recrystallisation from ethyl acetate.

20 ^1H NMR (CDCl_3 , 400MHz): 7.40 (2H, d, $J=8\text{Hz}$), 7.15 (2H, d, $J=8\text{Hz}$), 7.13 (2H, d, $J=8\text{Hz}$), 7.05 (2H, d, $J=8\text{Hz}$), 6.90 (1H, d $J=7.6\text{Hz}$), 6.75 (1H, d, $J=1.5\text{Hz}$), 6.65 (1H, bs s), 6.63 (1H, br s), 6.60 (1H, dd, $J=7.6, 1.5\text{Hz}$), 6.58 (1H, br s), 5.05 (2H, brs), 4.38 (1H, dd, $J=9.3\text{Hz}$), 4.30 (1H br d, $J=7\text{Hz}$), 4.25 (1H, dd, $J=9.6\text{Hz}$), 3.38 (1H, m), 2.32 (3H, s), 2.30 (3H, s) 2.28 (3H, s), 2.08 (3H, br s)

25

Example 2: Synthesis of 6(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (3)

Imidazole (0.166g) was added to a suspension of tetra-acetoxy 6(4-(isoflavan-4',7-diol))-isoflav-3-ene-4',7-diol (0.2g) in absolute ethanol (2.0ml). The mixture was refluxed under nitrogen for 12 hours. The solution was concentrated under vacuum and the product was precipitated by addition of deionised water (10ml). The mixture was left in the fridge

- 30 -

Articles:

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res.* 48, 589-601

Al-Maharik NI, Kaltia SAA, Mutikainen I, Wahala K. Synthesis of C-C-Bridged Bis-Isoflavones *Journal of Organic Chemistry* 65, 2305-2308, 2000

Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phyto-oestrogens: where are we now? *British Journal Of Nutrition* 79(5): 393-406 1998

Bolger R, Wiese TE, Ervin K, Nestich S, Checovich W (1998) Rapid screening of environmental chemicals for estrogen receptor binding capacity. *Environ Health Perspect*, 106, 551-7

Chang Y-C, Nair MG, Santell RC, and Helferich WG. Microwave-mediated synthesis of anticarcinogenic isoflavones from soybeans. *J Agric Food Chem.* 1994, 42, 1869-1871

Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, 1299 7th Edition, 1985

Moss RW, Cancer Therapy: the Independent Consumer's Guide to Non-Toxic Treatment and Prevention (New York: Equinox Press, 1992)

Panchagnula *et al.* (2000) Transdermal iontophoresis revisited. *Current Opinion in Chemical Biology* 4: 468-473

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other cell line. *Cancer Res.* 48(17); 4827-33.

- 33 -

wherein

$R_1, R_2, R_3, R_4, R_5, R_6, R_7$ and R_8 are independently hydrogen, hydroxy, OR_9 , $OC(O)H$, $OC(O)R_9$, $OS(O)R_9$, $OSi(R_{10})_3$, $C(O)R_{11}$, CO_2R_{12} , alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,

R_9 is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

R_{10} is independently hydrogen, alkyl or aryl,

R_{11} is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and

R_{12} is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,


X is O , NR_4 or S , and

the drawing "—" represents either a single bond or a double bond,

which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in formula (I) at least one of R_5, R_6, R_7 and R_8 is hydrogen, and

with the proviso that compounds of the formula:



wherein

when "—" is a single bond or a double bond, and

R_A and R_B are hydrogen or methyl,

then R_C and R_D are hydrogen, and

when "—" is a single bond and R_A is hydrogen,


then either R_B is hydrogen or methyl, R_C is hydroxy and R_D is hydrogen, or

R_B and R_C are hydrogen and R_D is methoxy,

are specifically excluded, and

- 33A -

with the proviso that compounds of the formula:




wherein

when "—" is a single bond or a double bond,
then R_G and R_H are hydrogen or methyl, and

when "—" is a single bond and R_G is methoxy,
 then R_H is hydroxy or benzyl,
 are specifically excluded.

- 33B -


2. A compound of claim 1 selected from the compounds of general formulae (Ia) and (IIa):




artery disease, stroke, myocardial infarction, hypertensive vascular disease, malignant hypertension, thromboangiitis obliterans, fibromuscular dysplasia;

- k) diseases and disorders associated with abnormal immunological responses including but limited to dermatomyositis and scleroderma;
- l) diseases and disorders associated with degenerative changes within the eye including but not limited to cataracts, macular degeneration, retinal atrophy,

and wherein the one or more compounds of formulae (I) and (II) are:





wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are independently hydrogen, hydroxy, OR₉, OC(O)H, OC(O)R₉, OS(O)R₉, OSi(R₁₀)₃, C(O)R₁₁, CO₂R₁₂, alkyl, haloalkyl, aryl, arylalkyl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo,

R₉ is alkyl, haloalkyl, aryl, arylalkyl or alkylaryl,

R₁₀ is independently hydrogen, alkyl or aryl,

R₁₁ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, and

R₁₂ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

X is O, NR₄ or S, and

the drawing "—" represents either a single bond or a double bond,

which compounds include pharmaceutically acceptable salts thereof,

with the proviso that in formula (I) at least one of R₅, R₆, R₇ and R₈ is hydrogen.

11. A method for the treatment, prophylaxis or amelioration of a disease or disorder which method includes the step of administering a therapeutically effective amount of one or more compounds of formulae (I) and (II) as defined in claim 10 to a subject, wherein the disease or disorder is selected from the group selected from:

- (i) conditions in women associated with abnormal estrogen/androgen balance including but not limited to cyclical mastalgia, acne, dysmenorrhoea, uterine fibroids, endometriosis, ovarian cysts, premenstrual syndrome, acute menopause symptoms, osteoporosis, senile dementia, infertility; and
- (ii) conditions in men associated with abnormal estrogen/androgen balance including but not limited to benign prostatic hypertrophy, infertility, gynecomastia, alopecia hereditaria and various other forms of baldness.

12. Use of one or more compounds of formulae (I) and (II) as defined in claim 10 in the manufacture of a medicament for the treatment of a disorder or disease.

13. Use of one or more compounds of formulae (I) and (II) as defined in claim 10 as an anti-estrogen or selective estrogen receptor modulator (SERM).

14. An agent for the treatment, prophylaxis or amelioration of a disease or disorder which agent comprises one or more compounds of formulae (I) or (II) as defined in claim 10.

15. A pharmaceutical composition which comprises one or more compounds of formulae (I) and (II) as defined in claim 10 in association with one or more pharmaceutical carriers and/or excipients.

16. A drink or food-stuff, which contains one or more compounds of formulae (I) and (II) as defined in claim 10.

17. A composition comprising one or more compounds of formulae (I) and (II) as defined in claim 10, vitamin E, and optionally a pharmaceutically, veterinarially or cosmetically acceptable carriers and/or excipients.